First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras

NCT01057017 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped possible lack of efficacy

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: intervention

Sponsor

Brown University

Collaborators

[object Object]
[object Object]